title: Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.
abstract: Several new therapeutic strategies are now considered for acute myeloid leukemia (AML) patients unfit for intensive chemotherapy, including modulation of protein lysine acetylation through inhibition of histone deacetylases (HDACs). These enzymes alter the acetylation of several proteins, including histones and transcription factors, as well as several other proteins directly involved in the regulation of cell proliferation, differentiation and apoptosis. Valproic acid (VPA) is a HDAC inhibitor that has been investigated in several clinical AML studies, usually in combination with all-trans retinoic acid (ATRA) for treatment of patients unfit for intensive chemotherapy, for example older patients, and many of these patients have relapsed or primary resistant leukemia. The toxicity of VPA in these patients is low and complete hematological remission lasting for several months has been reported for a few patients (<5% of included patients), but increased peripheral blood platelet counts are seen for 30 to 40% of patients and may last for up to 1 to 2 years. We review the biological effects of VPA on human AML cells, the results from clinical studies of VPA in the treatment of AML and the evidence for combining VPA with new targeted therapy. However, it should be emphasized that VPA has not been investigated in randomized clinical studies. Despite this lack of randomized studies, we conclude that disease-stabilizing treatment including VPA should be considered especially in unfit patients, because the possibility of improving normal blood values has been documented in several studies and the risk of clinically relevant toxicity is minimal.
authors.affiliation: Section for Hematology, Institute of Medicine, University of Bergen, N-5021, Bergen, Norway. hanne.fredly@med.uib.no.
authors.forename: Hanne
authors.initials: H
authors.lastname: Fredly
authors.forename: Bjørn Tore
authors.initials: BT
authors.lastname: Gjertsen
authors.forename: Oystein
authors.initials: O
authors.lastname: Bruserud
references.citation: Blood. 2000 Dec 1;96(12):3671-4
references.pmid: 11090046
references.citation: Exp Hematol. 2009 Jun;37(6):649-58
references.pmid: 19463767
references.citation: Lancet Oncol. 2009 Mar;10(3):223-32
references.pmid: 19230772
references.citation: Cancer Res. 2006 Sep 1;66(17):8903-11
references.pmid: 16951208
references.citation: Br J Haematol. 2009 Feb;144(3):332-41
references.pmid: 19036090
references.citation: Leukemia. 2004 Apr;18(4):809-16
references.pmid: 14762444
references.citation: Leukemia. 2012 May;26(5):910-7
references.pmid: 22064349
references.citation: Br J Haematol. 2010 Jul;150(1):72-82
references.pmid: 20456355
references.citation: Leukemia. 2009 Aug;23(8):1389-97
references.pmid: 19262596
references.citation: Leuk Res. 2009 Jun;33(6):779-87
references.pmid: 19007987
references.citation: Cancer Sci. 2010 Mar;101(3):609-15
references.pmid: 20028385
references.citation: Cancer. 2007 Sep 1;110(5):943-54
references.pmid: 17647267
references.citation: J Clin Oncol. 2009 Jan 1;27(1):61-9
references.pmid: 19047294
references.citation: Blood. 2008 Feb 1;111(3):1060-6
references.pmid: 17962510
references.citation: Oncotarget. 2010 May;1(1):34-42
references.pmid: 21293051
references.citation: Int J Biochem Cell Biol. 2009 Jan;41(1):72-80
references.pmid: 18948224
references.citation: Hematology. 2010 Oct;15(5):338-43
references.pmid: 20863429
references.citation: Curr Med Chem. 2002 Aug;9(15):1417-33
references.pmid: 12173980
references.citation: Clin Epigenetics. 2012 Feb 27;4(1):4
references.pmid: 22414433
references.citation: Curr Hematol Malig Rep. 2010 Apr;5(2):95-100
references.pmid: 20425402
references.citation: Leuk Res. 2011 May;35(5):620-5
references.pmid: 21176959
references.citation: Cancer. 2005 Dec 15;104(12):2717-25
references.pmid: 16294345
references.citation: Nat Rev Clin Oncol. 2012 Oct;9(10):579-90
references.pmid: 22949046
references.citation: Clin Epigenetics. 2013 Aug 01;5(1):13
references.pmid: 23915396
references.citation: Bone Marrow Res. 2012;2012:329061
references.pmid: 23082251
references.citation: Leuk Res. 2007 Oct;31(10):1403-11
references.pmid: 17445886
references.citation: Blood Cancer J. 2011 Feb;1(2):e4
references.pmid: 22829110
references.citation: Crit Rev Oncol Hematol. 2007 Oct;64(1):19-30
references.pmid: 17765568
references.citation: J Pharmacol Exp Ther. 2007 Jun;321(3):953-60
references.pmid: 17389244
references.citation: Ann Hematol. 2011 Aug;90(8):917-31
references.pmid: 21340723
references.citation: J Clin Oncol. 2011 Feb 10;29(5):487-94
references.pmid: 21220605
references.citation: Haematologica. 2005 Jul;90(7):986-8
references.pmid: 15996941
references.citation: Clin Epigenetics. 2011 Aug;2(2):197-212
references.pmid: 22704337
references.citation: Clin Epigenetics. 2012 Aug 31;4(1):12
references.pmid: 22935201
references.citation: Leukemia. 2005 Jul;19(7):1161-8
references.pmid: 15902297
references.citation: Leuk Res. 2010 Feb;34(2):235-42
references.pmid: 19539992
references.citation: Blood. 2009 Apr 30;113(18):4179-87
references.pmid: 19008455
references.citation: Cancer. 2005 Dec 15;104(12):2726-34
references.pmid: 16284985
references.citation: Blood. 2006 May 1;107(9):3481-5
references.pmid: 16455952
references.citation: Am J Hematol. 2012 Apr;87(4):368-76
references.pmid: 22374841
references.citation: Leukemia. 2006 Feb;20(2):212-7
references.pmid: 16357841
references.citation: Leukemia. 2006 Nov;20(11):2076-9
references.pmid: 16990768
references.citation: Curr Top Microbiol Immunol. 2007;313:101-28
references.pmid: 17217041
references.citation: Cell Cycle. 2008 Jul 15;7(14):2139-45
references.pmid: 18641459
references.citation: J Clin Oncol. 2010 Feb 1;28(4):562-9
references.pmid: 20026804
references.citation: Nat Genet. 1999 Jan;21(1):103-7
references.pmid: 9916800
references.citation: Int J Hematol. 2005 Jul;82(1):48-54
references.pmid: 16105759
references.citation: Clin Cancer Res. 2009 Jun 1;15(11):3705-15
references.pmid: 19458058
references.citation: Lancet. 2006 Nov 25;368(9550):1894-907
references.pmid: 17126723
references.citation: Eur J Haematol. 2005 Oct;75(4):293-8
references.pmid: 16146535
references.citation: J Biomed Biotechnol. 2010;2010:692097
references.pmid: 20625438
references.citation: Best Pract Res Clin Haematol. 2010 Dec;23(4):463-8
references.pmid: 21130408
references.citation: Haematologica. 2006 Nov;91(11):1513-22
references.pmid: 17082009
references.citation: Haematologica. 2012 May;97(5):739-42
references.pmid: 22133771
references.citation: Haematologica. 2009 Oct;94(10):1375-82
references.pmid: 19794082
references.citation: Leuk Lymphoma. 2012 Dec;53(12):2487-95
references.pmid: 22642934
references.citation: Blood. 2006 Mar 1;107(5):2094-7
references.pmid: 16304046
references.citation: Cancer Res. 2006 Jun 1;66(11):5875-82
references.pmid: 16740727
references.citation: J Natl Cancer Inst Monogr. 2008;(39):52-7
references.pmid: 18648004
references.citation: Onkologie. 2008 Nov;31(11):629-33
references.pmid: 19145098
references.citation: Cell. 2007 Feb 23;128(4):683-92
references.pmid: 17320506
references.citation: Transfus Med. 2013 Dec;23(6):397-406
references.pmid: 23919332
references.citation: Leuk Lymphoma. 2006 Oct;47(10):2062-9
references.pmid: 17071477
references.citation: Ann Oncol. 2006 Feb;17(2):281-5
references.pmid: 16373393
references.citation: Blood. 2010 Nov 25;116(22):4422-9
references.pmid: 20668231
references.citation: J Clin Oncol. 2010 Feb 1;28(4):556-61
references.pmid: 20026803
references.citation: Clin Epigenetics. 2011 Apr;2(1):27-53
references.pmid: 22704268
references.citation: Blood. 2008 Mar 1;111(5):2505-15
references.pmid: 18299451
references.citation: Haematologica. 2007 Apr;92(4):542-5
references.pmid: 17488665
references.citation: Oncology (Williston Park). 2011 Jul;25(8):733-41
references.pmid: 21874835
references.citation: J Clin Oncol. 2003 Dec 15;21(24):4642-9
references.pmid: 14673054
references.citation: Cancer Chemother Pharmacol. 2009 Jul;64(2):213-21
references.pmid: 19350240
references.citation: EMBO J. 2001 Dec 17;20(24):6969-78
references.pmid: 11742974
references.citation: Expert Opin Ther Targets. 2006 Feb;10(1):51-68
references.pmid: 16441228
references.citation: Br Med Bull. 2006;79-80:153-70
references.pmid: 17277075
references.citation: Leukemia. 2011 Jul;25(7):1122-7
references.pmid: 21475252
references.citation: Int J Oncol. 2007 Dec;31(6):1529-38
references.pmid: 17982680
references.citation: Cancer Treat Rev. 2004 Feb;30(1):103-17
references.pmid: 14766128
references.citation: Crit Rev Oncol Hematol. 2009 Feb;69(2):168-74
references.pmid: 18778950
references.citation: Blood. 2007 Oct 1;110(7):2302-8
references.pmid: 17596541
references.citation: Br J Haematol. 2007 Feb;136(4):624-7
references.pmid: 17223919
references.citation: Curr Pharm Biotechnol. 2007 Dec;8(6):388-400
references.pmid: 18289048
references.citation: Cell Stress Chaperones. 2008 Sep;13(3):357-64
references.pmid: 18386162
references.citation: Cancer. 2005 Jul 1;104(1):101-9
references.pmid: 15895376
references.citation: Eur J Pharm Sci. 2010 Oct 9;41(2):210-8
references.pmid: 20600877
references.citation: Leukemia. 2012 Jul;26(7):1630-7
references.pmid: 22333881
references.citation: Leuk Res. 2005 Sep;29(9):1049-58
references.pmid: 16038731
references.citation: Folia Biol (Praha). 2010;56(5):201-5
references.pmid: 21138651
references.citation: Blood. 2006 Jul 15;108(2):419-25
references.pmid: 16609072
references.citation: Haematologica. 2006 Dec;91(12):1653-61
references.pmid: 17145602
references.citation: Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):62-77
references.pmid: 19275578
references.citation: Blood. 2010 Sep 16;116(11):1908-18
references.pmid: 20530795
references.citation: Clin Epigenetics. 2010 Sep;1(1-2):25-44
references.pmid: 22704087
references.citation: Int J Clin Oncol. 2007 Oct;12(5):313-7
references.pmid: 17929112
references.citation: Blood. 1981 Jun;57(6):1000-4
references.pmid: 6939451
references.citation: Leuk Res. 2010 May;34(5):605-9
references.pmid: 19800118
references.citation: Leuk Res. 2011 Aug;35(8):991-7
references.pmid: 21474179
references.citation: Clin Epigenetics. 2010 Dec;1(3-4):117-136
references.pmid: 21258646
references.citation: Leuk Res. 2011 Sep;35(9):1212-8
references.pmid: 21632108
references.citation: J Clin Oncol. 2011 May 20;29(15):1987-96
references.pmid: 21483003
references.citation: PLoS One. 2012;7(11):e48992
references.pmid: 23155442
references.citation: Blood. 2006 Nov 15;108(10):3271-9
references.pmid: 16882711
references.citation: Expert Opin Investig Drugs. 2011 Feb;20(2):287-95
references.pmid: 21192773
references.citation: Leukemia. 2009 Apr;23(4):641-8
references.pmid: 19151770
references.citation: Anticancer Res. 2008 Mar-Apr;28(2A):855-64
references.pmid: 18507029
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3884-91
references.pmid: 17679729
references.citation: Leukemia. 2011 Feb;25(2):226-35
references.pmid: 21116282
references.citation: Clin Epigenetics. 2012 Mar 12;4(1):5
references.pmid: 22414492
references.citation: Oncol Rep. 2011 Jun;25(6):1549-56
references.pmid: 21431284
references.citation: Curr Hematol Malig Rep. 2006 Jun;1(2):69-74
references.pmid: 20425334
references.citation: Cancer Res. 2002 Dec 15;62(24):7213-8
references.pmid: 12499261
references.citation: Ann Hematol. 2005 Dec;84 Suppl 1:61-6
references.pmid: 16270213
references.citation: Ann Hematol. 2003 Aug;82(8):476-480
references.pmid: 12835916
references.citation: Epigenetics. 2008 Nov;3(6):342-9
references.pmid: 19011377
references.citation: Curr Cancer Drug Targets. 2008 Dec;8(8):666-75
references.pmid: 19075589
references.citation: J Cancer Res Clin Oncol. 2011 Jun;137(6):997-1003
references.pmid: 21152934
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4417-23
references.pmid: 21969499
references.citation: Curr Opin Oncol. 2008 Nov;20(6):705-10
references.pmid: 18841054
references.citation: Cancer. 2007 Mar 15;109(6):1114-24
references.pmid: 17315155
references.citation: J Clin Pharm Ther. 2008 Aug;33(4):331-8
references.pmid: 18613850
references.citation: Haematologica. 2009 Nov;94(11):1590-4
references.pmid: 19608675
references.citation: Semin Hematol. 2005 Jul;42(3 Suppl 2):S38-42
references.pmid: 16015504
references.citation: Leukemia. 1987 Aug;1(8):575-9
references.pmid: 3312846
references.citation: Arch Intern Med. 2002 Jul 22;162(14):1597-603
references.pmid: 12123403
references.citation: Ann Hematol. 2011 Apr;90(4):379-87
references.pmid: 20922525
references.citation: Cancer. 2006 Jan 1;106(1):112-9
references.pmid: 16323176
references.citation: Leukemia. 2005 Oct;19(10):1751-9
references.pmid: 16121216
references.citation: Cancer. 2008 Nov 1;113(9):2504-11
references.pmid: 18825661
references.citation: Leuk Lymphoma. 2012 Jun;53(6):1077-83
references.pmid: 22098405
references.citation: Eur J Clin Pharmacol. 2012 Sep;68(9):1233-42
references.pmid: 22421815